MaxCyte, Inc. vs Neuronetics, Inc.
Market value, revenue, profit, valuation and financial strength side by side, each from the company's own filings or market data, with its date.
In short
- MaxCyte, Inc. and Neuronetics, Inc. are worth about the same: $156 M and $162 M (market caps of Oct 27, 2026 for MaxCyte, Inc. and Oct 23, 2026 for Neuronetics, Inc.).
- Neuronetics, Inc. had more revenue: $149 M against $33 M for MaxCyte, Inc., both in the year to December 2025.
- Both made a net loss: $45 M for MaxCyte, Inc. and $39 M for Neuronetics, Inc.
- Neuronetics, Inc. keeps more of each dollar of sales: a net margin of -26.1% against -135.1% for MaxCyte, Inc.
- Neuronetics, Inc.'s revenue grew faster in its latest fiscal year: +99.2% against -14.5% for MaxCyte, Inc.
- Both are in the distress zone of the Altman Z-score.
Market value, the same start = 100
From Jan 2022: how each one's value moved, whatever its size.
Revenue by fiscal year
US$ billions, as reported in each year's annual results.
Side by side
| Measure | MaxCyte, Inc. MXCT · #17,164 in the world | Neuronetics, Inc. STIM · #17,042 in the world |
|---|---|---|
| Profile | ||
| Country | 🇺🇸 USA | 🇺🇸 USA |
| Sector | Healthcare | Healthcare |
| Industry | Diagnostics and Research | Diagnostics and Research |
| Founded | 1998 | 2003 |
| Size | ||
| Market cap | $156 M | $162 M |
| Revenue | $33 M | $149 M |
| Net income | $-45 M | $-39 M▲ best |
| Employees | 91 | — |
| Valuation | ||
| Price to sales | 4.5× | 1.0× |
| Price to book | 0.9× | 7.2× |
| Free cash flow yield | -23.2% | -13.1%▲ best |
| Profitability | ||
| Gross margin | 81.1%▲ best | 48.5% |
| Operating margin | -157.1% | -21.1%▲ best |
| Net margin | -135.1% | -26.1%▲ best |
| Return on equity | -23.6%▲ best | -155.7% |
| Growth | ||
| Revenue growth | -14.5% | 99.2%▲ best |
| Revenue growth, 3 years a year | -9.3% | 31.8%▲ best |
| Financial strength | ||
| Debt to equity | — | 2.9× |
| Interest cover | — | -4.1× |
| Cash | ||
| Free cash flow margin | -109.5% | -14.2%▲ best |
| Strength scores | ||
| Piotroski F-score | — | 4 of 9 |
| Altman Z-score zone | distress | distress |
| Data as of | Market cap Oct 2026; ratios FY2025 | Market cap Oct 2026; ratios FY2025 |
▲ marks the better of the two where higher or lower is better; size and valuation multiples are marked for neither
Questions and answers#
Which is bigger, MaxCyte, Inc. or Neuronetics, Inc.?
MaxCyte, Inc. and Neuronetics, Inc. are worth about the same: $156 M and $162 M (market caps of Oct 27, 2026 for MaxCyte, Inc. and Oct 23, 2026 for Neuronetics, Inc.).
Which makes more money, MaxCyte, Inc. or Neuronetics, Inc.?
Neuronetics, Inc. had more revenue: $149 M against $33 M for MaxCyte, Inc., both in the year to December 2025. Both made a net loss: $45 M for MaxCyte, Inc. and $39 M for Neuronetics, Inc.
Which is more profitable, MaxCyte, Inc. or Neuronetics, Inc.?
Neuronetics, Inc. keeps more of each dollar of sales: a net margin of -26.1% against -135.1% for MaxCyte, Inc.
Which is growing faster, MaxCyte, Inc. or Neuronetics, Inc.?
Neuronetics, Inc.'s revenue grew faster in its latest fiscal year: +99.2% against -14.5% for MaxCyte, Inc.
Which is financially stronger, MaxCyte, Inc. or Neuronetics, Inc.?
Both are in the distress zone of the Altman Z-score.
More about MaxCyte, Inc.
More about Neuronetics, Inc.
Sources#
Every figure on this page comes from these, with the date shown next to it.